Lithea a Swedish company working on new ways to treat cancer by delivering medicine directly into tumors, has successfully raised € 850.000 (SEK 9.3 Million) from its current investors. This funding shows strong ongoing support and marks an important step toward testing its treatment in humans.
Lithea’s platform can be used with many types of cancer drugs and may eventually be applied to other common cancers like breast, lung, and prostate. With a skilled team, strong patent protection, and a clear plan for approval, Lithea is making steady progress toward its first human trials.
“We’re building a platform that combines precision with flexibility. The CaS/HA system allows us to deliver cancer drugs exactly where they’re needed, and we’re excited about its potential to improve outcomes for patients with difficult-to-treat tumors.”
says Dr. Deepak Raina, CTO and co-founder of Lithea
The money will be used to continue developing Lithea’s unique drug delivery system and to prepare its lead product, LIT1001, for clinical trials. This includes more lab studies to confirm safety and effectiveness, as well as preparations for manufacturing and regulatory approval.
LIT1001 is a small pellet filled with the chemotherapy drug doxorubicin. It’s designed to be placed directly into bone tumors, specifically targeting osteosarcoma, a rare and aggressive cancer mostly affecting children. By delivering the drug straight into the tumor, LIT1001 aims to fight cancer more effectively while reducing harmful side effects.
“Our technology has shown very promising results in animal studies, with 92% reduction in tumor size and much lower drug levels in the rest of the body compared to standard treatment. This funding helps us build stronger scientific proof and move closer to testing in patients,”
says Ludvig Sjöberg, CEO at Lithea
The product has already received special recognition from the U.S. FDA as an Orphan Drug, which helps speed up its development and approval process.
